Skip to main content

Edgewise Therapeutics, Inc.

EWTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001710072

In the last 90 days, Edgewise Therapeutics, Inc. insiders filed 0 open-market purchases and 6 sales; 226 institutions reported holding it in 13F filings for Q2 2026, worth $4.82B in total; no superinvestor holds it.

Superinvestors holding EWTX, Q2 2026

See all superinvestors

No superinvestor reported holding EWTX in Q2 2026.

Moves by quarter

Superinvestors that opened, added to, trimmed or sold out of EWTX each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.

  1. Q2 2025

    0 superinvestors holding at quarter end

    Sold out
    Viking Global Investors
  2. Q1 2025

    1 superinvestor holding at quarter end

    Reduced
    Viking Global Investors (−60.0%)
  3. Q4 2024

    1 superinvestor holding at quarter end

    Reduced
    Viking Global Investors (−17.3%)
  4. Q2 2024

    1 superinvestor holding at quarter end

    Reduced
    Viking Global Investors (−55.6%)
  5. Q1 2024

    1 superinvestor holding at quarter end

    Reduced
    Viking Global Investors (−45.8%)
  6. Q3 2023

    1 superinvestor holding at quarter end

    Added
    Viking Global Investors (+3.6%)
  7. Q2 2023

    1 superinvestor holding at quarter end

    Added
    Viking Global Investors (+21.1%)
  8. Q1 2023

    1 superinvestor holding at quarter end

    Added
    Viking Global Investors (+11.3%)
  9. Q3 2022

    1 superinvestor holding at quarter end

    Added
    Viking Global Investors (+61.7%)
  10. Q2 2021

    1 superinvestor holding at quarter end

    Reduced
    Viking Global Investors (−18.6%)